Abushakra, Susan

Aducanumab, gantenerumab, BAN2401, and ALZ-801—The first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 354

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 275

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 258

CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL

Abushakra, S., Porsteinsson, A., Scheltens, P., Sadowsky, C., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Wang, P., et al. (2017) · The Journal of Prevention of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 75